论文部分内容阅读
目的探讨干扰素α-2b联合阿德福韦酯治疗乙肝e抗原(HBe Ag)阳性慢性乙型肝炎临床疗效和安全性。方法 82例HBe Ag阳性慢性乙型肝炎患者根据治疗方法的不同分为观察组和对照组,观察组50例采用干扰素α-2b联合阿德福韦酯治疗,对照组32例单纯采用干扰素α-2b治疗,两组均治疗1年后观察疗效和不良反应。结果治疗后观察组HBe Ag阴转率、HBe Ag血清转换率、谷氨酸转氨酶(ALT)复常率和HBV-DNA阴转率均显著高于对照组,差异均有统计学意义(P<0.05);两组不良反应比较差异无统计学意义(P>0.05)。结论干扰素α-2b联合阿德福韦酯治疗HBe Ag阳性慢性乙型肝炎疗效显著且不增加不良反应,值得临床积极推广。
Objective To investigate the clinical efficacy and safety of interferon α-2b combined with adefovir dipivoxil in the treatment of hepatitis B e antigen-positive chronic hepatitis B patients. Methods Eighty-two patients with HBeAg-positive chronic hepatitis B were divided into observation group and control group according to different treatment methods. Fifty patients in observation group were treated with interferon alfa-2b combined with adefovir dipivoxil, and 32 in control group were treated with interferon α-2b treatment, the two groups were treated for 1 year after treatment to observe the efficacy and adverse reactions. Results After treatment, the negative rate of HBeAg, HBeAg seroconversion, ALT normalization rate and HBV-DNA negative conversion rate in the observation group were significantly higher than those in the control group (P < 0.05). There was no significant difference in adverse reactions between the two groups (P> 0.05). Conclusion Interferon α-2b combined with adefovir dipivoxil treatment of HBeAg-positive chronic hepatitis B significant effect without increasing adverse reactions, it is worth actively clinical promotion.